The tumour suppressor p53 is a multifunctional protein important for the maintenance of genomic integrity. It is able to form molecular complexes with dierent DNA targets and also with cellular proteins involved in DNA transcription and DNA repair. In mammalian cells the biochemical processing of DNA occurs on a nuclear substructure termed the nuclear matrix. Previously Deppert and co-workers have identi®ed p53 in association with the nuclear matrix in viral-and non-viral transformed cell lines. In the present study we demonstrate, for the ®rst time, that p53 is bound to the nuclear matrix in primary cultures of normal mammalian cells and that this binding increases following DNA damage. Analysis of cell lines expressing structural mutants of p53 revealed that association with the nuclear matrix is independent of the tertiary and quaternary structure of p53. However, the proline-rich domain towards the Nterminus of p53 (residues 67 to 98) appeared important for binding to the nuclear matrix. This was demonstrated by TET-ON regulated expression of p53-derived constructs in p53 7/7 murine embryonic ®broblasts (MEF p53
Introduction
This study concerns the sub-nuclear compartmentalization of the tumour suppressor p53 and its association with the nuclear matrix in normal mammalian cells.
The nuclear matrix is a non-chromatin sub-structure of the nucleus. It is a fundamentally important nuclear component upon which the processes of DNA replication, recombination, repair and transcription take place. The processing of hnRNA also occurs at the nuclear matrix. Protein interactions with the nuclear matrix include protein complexes involved in the biochemical processing of DNA and RNA, regulatory proteins involved in cell cycle control, and regulatory proteins which link nuclear responses to exogenous stimulae. In addition the nuclear matrix binds speci®c elements of chromosomal DNA (termed matrix attachment regions or MARs) and is believed to play a part in the spatial and functional organization of chromatin. Thus, the nuclear matrix provides a nuclear sub-structure upon which chromatin is organized, DNA and RNA are processed, and dierential gene expression may be managed (for examples and reviews on the nuclear matrix see Berezney and Coey, 1974; Berezney et al., 1995; Pardoll and Vogelstein, 1980; Spector, 1993; Jackson and Cook, 1995; Mittnacht and Weinberg, 1991; Mancini et al., 1994; Boulikas, 1995; Penman, 1995; Nickerson et al., 1997; Stenoien et al., 1998; Stratling and Yu, 1999; Deppert, 2000; Cook, 1991 Cook, , 2001 .
The p53 tumour suppressor protein is constitutively expressed in normal cells and nuclear localization is important for its ability to function in response to genotoxic stress (reviewed in Jimenez et al., 1999) . Exposure of cells to genotoxic agents activates p53 as a transcription factor, able to orchestrate the expression of genes involved in cell growth arrest and apoptosis (reviewed in May and May, 1999) . Under normal conditions of growth the p53 protein exists at very low levels and is inactive for the transactivation of target genes such as p21 and mdm2 (see May and May, 1999; Vogelstein et al., 2000; Ljungman, 2000 for recent reviews). Under these conditions dierent sub-sets of nuclear p53 can be identi®ed by combined microscopy and biochemical analyses (Rubbi and Milner, 2000) . Approximately half the protein is soluble in the nucleoplasm and is released following permeabilization of the nuclear membrane. The residual nuclear-bound p53 is distributed between dierent nuclear substructures and co-localizes with transcription sites of pre-mRNA synthesis (RNA polymerase II) and of rRNA synthesis (within nucleoli, RNA polymerase I).
Additional foci of nuclear-bound p53 are distributed throughout the nucleus (Rubbi and Milner, 2000) . Binding of p53 to nuclear sub-structures indicates that it can associate, directly or indirectly, with the nuclear matrix. In order to investigate this possibility further we have now examined the sub-nuclear partitioning of p53 following biochemical fractionation of the nucleus.
We now demonstrate, for the ®rst time, that p53 associates with the nuclear matrix in normal cells and that this association increases following DNA damage. Analysis of cell lines expressing structural mutants of p53 revealed that the association with the nuclear matrix is independent of the tertiary and quaternary structure of p53. However, the proline-rich domain towards the N-terminus of p53 (residues 67 to 98) appeared important for binding to the nuclear matrix. This was demonstrated by TET-ON regulated expression of p53-derived constructs in murine p53 7/7 embryonic ®broblasts. The proline-rich domain of p53 has the potential for SH3 protein ± protein interaction (Walker and and has a role in p53-mediated apoptosis (Ruaro et al., 1997; Sakamuro et al., 1997; Venot et al., 1998) . It may also be implicated in the ability of p53 to stimulate base excision repair of DNA damage (Zhou et al., 2001) . We believe that the positioning of p53 at the nuclear matrix is likely to prove important for its ability to respond to endogenous and exogenous events that adversely in¯uence genetic processing and/or the integrity of DNA.
Results
Primary cultures of human diploid ®broblasts and mouse embryonic ®broblasts were employed to study the sub-cellular distribution of endogenous p53 in normal cells by fractionation. Use of primary cells is important since there is recent evidence that the substructural organization of the nucleus may alter following immortalization of cells in culture (Kennedy et al., 2000) . Cells were harvested and fractionated as described in Materials and methods. Brie¯y, nuclei were isolated and subjected to sequential extraction steps with high salt, DNaseI, and RNase A. The residual insoluble pellet contains major components of the nuclear matrix, and was negative for histone H2A (not shown). Controls con®rmed the predicted distribution of nuclear proteins including, for example, the nuclear structural protein lamin B1 (Figure 1a ).
p53 is associated with the nuclear matrix
Under normal conditions of growth wild type p53 protein was detectable (by immunoblotting) in association with the nuclear matrix in both human and murine ®broblasts (Figure 1b) . In human normal diploid ®broblasts (NDFs) p53 was exclusively nuclear and predominantly associated with the nuclear matrix. In murine embryonic ®broblasts (MEFs) the pattern was slightly dierent in that roughly equivalent amounts of p53 were detectable in the cytoplasmic and nuclear fractions (see Figure 1b) . Most of the nuclear p53 in MEF cells was soluble and resolved as a doublet on SDS ± PAGE. The upper band was predominant and a faint band at this same level was also detectable in the nuclear matrix fraction ( Figure  1b ). These results demonstrate that wild type p53 can associate with the nuclear matrix in normal, nonstressed human and murine cells. This is consistent with the presence of nuclear-bound foci of p53 revealed throughout the nucleus by confocal scanning of immuno-stained cells (Rubbi and Milner, 2000) .
DNA damage increases p53 interaction with the nuclear matrix
To ask if the nuclear matrix fraction of p53 is modulated in response to DNA damage, cultures of murine embryonic ®broblasts cells were treated with cisplatin (10 mg ml
71
) for 6 h prior to fractionation. As expected, cisplatin induced an increase in the total amount of cellular p53 (Figure 1b , MEF+Cis). On fractionation the level of p53 bound to the nuclear matrix was shown to be increased relative to the untreated control cells (approximately ®vefold increase as assessed by scanning of the gels, Figure 1e ). These results indicate that perturbation of chromatin DNA structure by cisplatin induces an increase in the binding of p53 to the nuclear matrix. Transcription factors are normally released into the soluble phase during the fractionation procedure. Thus the observed increase in nuclear matrix binding by p53 is unlikely to represent activated p53 present in transcription initiation complexes.
p53 associates with the nuclear matrix in transformed cell lines To ask if p53 retains its ability to associate with the nuclear matrix in transformed cells we used two human epithelial cell lines, HCT116 and SW48. Both are derived from human colorectal carcinoma: HCT116 expresses wild type p53 whilst SW48 cells express mutant p53 (R248W; human p53 numbering is used throughout). In both of the transformed cell lines a sub-population of p53 molecules was associated with the nuclear matrix ( Figure 1c ). In addition both cell lines showed high levels of cytoplasmic p53. The only observed dierence between the distribution of wild type and mutant p53 was the relatively high level of wild type p53 in the nucleoplasmic fraction of HCT116 cells (Figure 1c ). In contrast, mutant p53 R248W was barely detectable in the nucleoplasmic fraction of SW48 cells. The R248W mutation aects the R248 DNA contact residue of p53 (Cho et al., 1994) . This same residue is also involved in p53 protein ± protein binding to p53-binding protein 2 (53BP2; Gorina and Pavletich, 1996) . Since p53 in SW48 cells is present in the nuclear matrix fraction (Figure 1c ) our present results indicate that R248 is not necessary for the association of p53 with the nuclear matrix. Two transformed murine ®broblast cell lines expressing de®ned structural mutants of p53 were next selected for study. Both cell lines express elevated levels of p53 and nuclear-bound p53 foci are evident throughout the nuclei following permeabilization under physiological conditions (Rubbi and Milner, 2000) . The ®rst cell line, 3T3tx, expresses endogenous p53 with mutations at codons 230 and 287 (Milner et al., 1993) . The mutant protein is structurally abnormal as determined by reactivity with conformation-dependent monoclonal antibodies (Milner et al., 1993) . Previous studies, using simple cell fractionation, indicated that endogenous mutant p53 in 3T3tx cells is predominantly cytoplasmic (Zerrahn et al., 1992) . Our present results con®rm this observation (Figure 1d , 3T3tx). Following nuclear fractionation approximately half the nuclear component of mutant p53 in 3T3tx cells was found to be associated with the nuclear matrix and the rest was nucleoplasmic ( Figure 1d ). It should be noted that cytoplasmic intermediate ®laments, including vimentin, are a contaminant of the nuclear matrix fraction (not shown) and that a conformational mutant of murine p53 has been reported to bind cytoplasmic vimentin ®laments in rat ®broblasts (clone 6 cells; Klotzsche et al., 1998) . However, no evidence for p53 association with cytoplasmic ®laments was evident following permeabilization of 3T3tx cells, whereas internally bound nuclear p53 was clearly evident in these cells (Rubbi and Milner, 2000) . In its wild type conformation p53 does not appear to bind vimentin (Jiang, Warnock and Milner, unpublished results). The second cell line, T3T3, expresses mutant p53 in the wild type conformation but with abnormal quaternary assembly into tetrameric and higher order complexes (Milner et al., 1993) . On fractionation the T3T3 cells displayed roughly equivalent amounts of nuclear and cytoplasmic p53 (Figure 1d ), again consistent with the previous results of Zerrahn et al. (1992) . For the nuclear p53, approximately 60% was soluble. The majority of the nuclear-bound p53 was complexed with the nuclear matrix (Figure 1d, T3T3 ). An unexpected observation with T3T3 cell extractions was the apparent increase in detectable nuclear p53 following nuclear lysis and fractionation ( Figure 1d , nuclei compared with nucleoplasm plus nuclear matrix samples). This was reproducible and was observed in three separate experiments with T3T3 cells: the explanation is unclear, presumably the fractionation procedure in some way increases the availability of the Pab240 epitope for antibody recognition in this particular cell line. In this context it is relevant to note that monomeric p53 in T3T3 cells may be complexed with a low molecular weight protein (Milner Figure 1 Distribution of endogenous p53 between dierent subcellular compartments following cytoplasmic and nuclear fractionation. Cells were harvested and the nuclei separated from the cytoplasmic fraction; isolated nuclei were then subjected to sequential fractionation steps as described in Materials and methods. The residual pellet fraction contains components of the nuclear matrix. Proteins were detected by immunoblotting (Materials and methods). (a) Shows the distribution of lamin B1, a nuclear skeletal protein predicted to fractionate with the nuclear and nuclear matrix fractions and employed to validate the fractionation protocol. (b) Shows p53 distribution in human normal diploid ®broblasts (NDF) and in normal mouse embryonic ®broblasts (MEF). The eects of DNA damage were studied by treating a parallel culture of MEFs with 10 mg ml Overall, the above results demonstrate that nuclearbound p53 is associated with the nuclear matrix in normal cells and that this association increases following treatment of mouse embryonic ®broblasts with cisplatin (Figure 1b,e) . Binding to the nuclear matrix by p53 is also indicated for endogenous mutant p53 proteins in human and murine transformed cells. Mutants include (i) p53 R248W which aects both sequence-speci®c DNA binding by p53 and protein ± protein binding with 53BP2 ( Figure 1c , SW48); (ii) mutant p53 with abnormal conformational structure (3T3tx; Figure 1d) ; and (iii) mutant p53 with abnormal oligomerization (T3T3 cells; Figure 1d ). Thus nuclear matrix binding by p53 is independent of wild type protein structure at both the tertiary and quaternary level, and is also unaected by the R248W mutation in the central core domain.
Selection and exogenous expression of truncated p53 proteins used to map nuclear matrix binding
In order to characterize the binding requirements between p53 and the nuclear matrix in more detail we next expressed truncated p53 constructs in p53 7/7 cells using primary cultures of murine embryonic ®broblasts lacking both p53 alleles (MEF p53 7/7 ; Donehower et al., 1992) . The choice of truncated p53 proteins was guided by our previous observation that wild type, but not mutant p53 undergoes selective proteolytic cleavage when exposed to lesion DNA (Molinari et al., 1996; Okorokov et al., 1997; Mee et al., 1999) . Using microsequencing we have now determined the N-terminal cleavage sites for each of the p53 cleavage products (see Figure 2) . Two Nterminal cleavage sites were identi®ed at residues 23/24 (tryptophan/lysine) and 66/67 (serine/glycine). It is intriguing to note that these N-terminal cleavage sites, generated in response to DNA damage, are positioned between structural/functional domains of the p53 protein (indicated in Figure 2) . Moreover, the ®rst cleavage site at residues 23 and 24 is predicted to abolish sequence-speci®c transactivation of p53 target genes and also the interaction with p53 regulatory proteins such as mdm2, TAFs and p300 (Lin et al., 1994 (Lin et al., , 1995 Lu and Levine, 1995; Gu and Roeder, 1997) . The second N-terminal cleavage site at residues 66/67 is positioned between the N-terminal transactivation-domain and the proline-rich domain of p53 (see Figure 2) .
Induced proteolytic cleavage of p53 at residues 23/24 generates a 50 kDa N-terminal cleavage product p53 [24 ± 393] which remains bound to p53/lesion DNA complexes. The second cleavage site at residues 66/67 marks the N-terminus of two additional cleavage products: a 40 kDa product, p53 [67 ± 393], which appears to be an intermediate cleavage product and a 35 kDa cleavage product which is released from p53-DNA complexes (Molinari et al., 1996; Okorokov et al., 1997; Mee et al., 1999) . In order to delineate the Cterminus of the 35 kDa cleavage product we constructed dierent C-terminal truncations at residues 303, 315 and 323 and compared their electrophoretic mobilities with the bona ®de 35 kDa product (results not shown). By this means we identi®ed p53 [67 ± 303] as being closest, if not identical to the 35 kDa cleavage product of p53.
The p53 [67 ± 303] cleavage product was selected for further study of nuclear matrix binding since it contains two discrete protein ± protein binding domains. The ®rst is the proline-rich domain, previously identi®ed as a putative protein binding domain with PXXP motifs characteristic of SH3 ligands (Walker and Ruaro et al., 1997; Sakamuro et al., 1997; Venot et al., 1998) . A second, unusual SH3 ligand is formed by the tertiary folding of the central Figure 2 Schematic showing domains of the p53 protein and N-and C-terminal proteolytic cleavage sites. N-terminal proteolytic cleavage sites were determined by microsequencing p53 cleavage products generated by incubation of puri®ed p53 with lesion DNA oligonucleotide (as detailed in Okorokov et al., 1997 (Figure 4a ). Intranuclear localization was con®rmed by confocal scanning (not shown) and nuclear uptake may involve passive diusion since p53 [67 ± 303] lacks nuclear localization signals. The truncated protein retained the wild type conformation of the p53 core domain, as determined by reactivity with conformation-dependent monoclonal antibodies (Figure 4b) . The protein resolved as a single monomeric peak on size fractionation by fast performance liquid chromatography (FPLC; Figure 4c ). Following cell fractionation approximately equal amounts of p53 [67 ± 303] were distributed between the cytoplasmic and nuclear fractions (Figure 4d ). Sequential fractionation of the nuclei revealed that the high level of protein retained in isolated nuclei was associated with the nuclear matrix (Figure 4d) . Indeed, association with the nuclear matrix appeared to account for all nuclear p53 [67 ± 303] although we cannot rule out the possible loss of soluble nucleoplasmic p53 by passive diusion through nuclear pores during preparation of the nuclear pellet. Punctate staining with discrete foci of matrix-bound p53 was observed following immunostaining of the extracted cell nuclei (Figure 4e) .
The above results demonstrate that p53 [67 ± 303] is expressed as a conformationally intact, monomeric protein in MEF p53 7/7 cells and accumulates to relatively high levels in both the nucleus and cytoplasm. The soluble protein was monomeric ( Figure  4c ) even though it has inherent capacity for protein ± protein binding via two discrete SH3 domains. This indicates lack of protein complexing with soluble proteins in the cytoplasm or nucleoplasm. However, protein ± protein interaction might account for the binding of p53 [67 ± 303] at the nuclear matrix ( Figure  4d ,e).
Nuclear matrix binding involves the proline-rich domain
To ask if the proline-rich domain is involved in the interaction of p53 with the nuclear matrix we generated a construct, p53 [98 ± 303] which lacks the proline-rich domain but which contains the complete central core domain of p53 (see Figure 2) . When expressed in p53 7/7 MEFs the truncated p53 [98 ± 303] protein was both nuclear and cytoplasmic (Figure 5a ), adopted the wild type core conformation (Figure 5b) , and was monomeric (Figure 5c ). Thus the intracellular distribution and structural properties of p53 [98 ± 303] were similar to those of p53 [67 ± 303] . However, a marked dierence was observed on biochemical fractionation. Most of the core protein was soluble and hardly any binding to the nuclear matrix was evident either by immunoblotting or by immunostaining (Figure 5d and e respectively). Thus we conclude that deletion of the proline rich domain drastically reduces the ability of p53 to associate with the nuclear matrix. Nonetheless, minimal matrix binding by p53 [98 ± 303] (Figure 5d ) was a consistent observation and indicates that the core domain of p53 also contributes to the localization of p53 at the nuclear matrix. 
Effects on cell cycle progression
Given the clear-cut dierence in nuclear matrix binding by p53 [67 ± 303] and p53 [98 ± 303] we were interested to ask if either protein has an eect on cell cycle progression. Since both truncated products lack the N-terminal transactivation domain of p53 any eect would presumably involve transcription-independent functions of p53. Moreover, both p53 [67 ± 303] and p53 [98 ± 303] failed to bind sequence-speci®c DNA targets containing either the consensus sequence for p53 (CON), or derived from p53-binding elements Figure  6a ). This eect was more pronounced following transient transfection (Figure 7a ): it is interesting to note that others have also reported more pronounced cell cycle arrest following transient-compared with stable expression of p53 (Walker and Levine, 1996) . In contrast, no cell cycle eect was observed in the presence of p53 [98 ± 303] following either induced (Figure 6b ) or transient expression (Figure 7c ). Thus deletion of the proline-rich domain, and corresponding loss of binding to the nuclear matrix, correlates with loss of partial G1 arrest. At present we have no explanation for this observation. One possibility is that matrix binding by p53 [67 ± 303] in some way interferes with the assembly of DNA replicative complexes on the nuclear matrix (see Discussion). Whatever the explanation, p53 [67 ± 303] reproducibly caused an increase in the population of cells in G1 of the cell cycle.
These cell cycle studies were extended to include a mutant, p53 [67 ± 303] R248H, which also retained the ability to induce partial G1 arrest (Figure 7b ). Earlier studies have reported that endogenous mutant p53 can induce viable G1 growth arrest Deppert et al., 1990) and it is possible that nuclear matrix binding by the mutant protein may be implicated in the growth inhibitory eect.
Discussion
In this work we show that a sub-fraction of p53 in normal mammalian cells is associated with the nuclear matrix. Matrix association in transformed cell lines expressing endogenous mutants of p53 indicates that wild type conformational structure of p53 and its assembly into tetramers are not required for binding to the nuclear matrix (Results section; Figure 1b) . Nonetheless, it remains possible that the matrix binding targets dier for wild type and mutant p53 proteins. For example, mutant but not wild type p53 binds MAR elements of chromosomal DNA (Will et al., Deppert and Schirmbeck, 1995) . Such binding might protect matrix bound MAR elements from DNaseI digestion and thus tether mutant p53 at the nuclear matrix.
The domains required for the binding of wild type p53 to the nuclear matrix were investigated using a truncated construct which encompasses two discrete protein ± protein binding domains, within the prolinerich domain and the central core domain of p53. This construct, p53 [67 ± 303] showed strong binding to the nuclear matrix when expressed in p53 7/7 mouse embryo ®broblasts. However, deletion of the prolinerich domain caused almost complete loss of matrix binding (Results section). Involvement of the prolinerich domain in binding p53 to the matrix is of particular interest since this domain is required for induction of apoptosis by mechanisms which are, as yet, poorly understood (Ruaro et al., 1997; Sakamuro et al., 1997; Venot et al., 1998) . Our present results thus raise the possibility of a mechanistic link between nuclear matrix binding by p53 and p53-dependent apoptotic pathway(s). Clearly it will be important to identify the matrix target proteins for p53 binding. Once target proteins are identi®ed the possibility that matrix binding by p53 directly contributes to p53-induced apoptosis can be investigated.
The association of endogenous p53 with the nuclear matrix and its increase following DNA damage also raises the possibility that matrix interaction may play a role during the p53 response to DNA damage. For example, it is already established that p53 can bind proteins involved in DNA repair, such as replication protein A (RPA; Dutta et al., 1993) , and helicases XPB and XPD (Wang et al., 1995; Leveillard et al., 1996) . Thus p53 may help recruit DNA repair proteins to DNA processing sites on the nuclear matrix. Such a role would be consistent with the ability of p53 to facilitate DNA repair by base excision repair (Oer et al., 1999 (Oer et al., , 2001 Zhou et al., 2001 ) and nucleotide excision repair pathways (Rubbi and Milner, p53 Workshop, Monterey, USA 2000, and manuscript in preparation).
In their pioneering studies on the nuclear distribution of SV40 large T antigen, Staufenbiel and Deppert (1983) noted that a sub-population of large T was associated with the nuclear matrix in SV40-transformed cell lines. In this work p53 was observed to co-immunoprecipitate with large T from the nuclear matrix fraction and this was attributed to large T antigen binding to the nuclear matrix. However, our present observation that p53 binds directly to the nuclear matrix, in the absence of large T, suggests that it may be p53 that sequesters SV40 large T to the nuclear matrix, rather than the other way round. Indeed, free p53 has been reported in nuclear matrix fractions of SV40-transformed cells (Deppert and Haug, 1986) . Mutants of SV40 large T that fail to interact with p53 also fail to bind the nuclear matrix (Deppert et al., 1989) and are transformation defective (Peden et al., 1989 (Peden et al., , 1998 . This raises the possibility that the sub-nuclear positioning of large T by p53 contributes towards the transforming potential of SV40 large T. In this context it is interesting to note that the association of large T with p300/CPB is also linked with its binding capacity for p53 and it has been suggested that p53 may mediate large T interaction with p300/CBP (Avantaggiati et al., 1996; Eckner et al., 1996; Lill et al., 1997) . Our present results indicate that any such cooperative interaction involving p53 may take place at the nuclear matrix.
In summary, using primary cell lines we now demonstrate that association with the nuclear matrix is a normal property of p53. Another tumour suppressor which also associates with the nuclear matrix is the retinoblastoma protein Rb (Mittnacht and Weinberg, 1991; Mancini et al., 1994) . Nuclear matrix binding by Rb is cell cycle dependent and is restricted to the hypophosphorylated form. Future studies will explore the possibility that p53 binding to the nuclear matrix may also be cell cycle dependent and/or regulated by post-translational modi®cation such as phosphorylation and acetylation. The importance of the proline-rich domain in binding p53 to the nuclear matrix is particularly interesting and may provide a lead towards understanding the link between the proline-rich domain and p53-dependent apoptosis. The binding of p53 to the nuclear matrix opens new considerations for studying the functional capacity of this multifunctional protein and its roles in the maintenance of genomic integrity.
Materials and methods

Cell lines and cell cultures
Primary human normal diploid ®broblasts (NDFs) were cultured in MEM supplemented with non-essential amino acids and 15% foetal calf serum (FCS). Transformed human epithelial cell lines HCT116 and SW48 were cultured in DMEM plus 10% FCS. Primary murine embryonic ®bro-blasts p53 7/7 (MEF p53
) were cultured in DMEM with 10% FCS (Life Technologies). Primary MEFs p53 +/+ were cultured in DMEM with 10% FCS, with supplements of 1.0 mM sodium pyruvate, 16non-essential amino acids, and 16insulin-transferring selenium-X. Transformed murine ®broblast cell lines T3T3 and 3T3tx were cultured in RPMI with 10% FCS. All were cultured at 378C in 5% CO 2 in air.
Plasmids, transfection and cell cloning
The p53 [67 ± 303], p53 [67 ± 303] R248H and p53 [98 ± 303] constructs were cloned into pcDNA3 (Introgen) for transient transfection and sub-cloned into pTRE (Clontech) for generating inducible cell lines. Transfection was carried out using Lipofectamine (Life Technologies). The TET-ON inducible system was used according to the manufacturer's instructions (Clontech, TET-OFF and TET-ON Gene Expression Systems and Cell Lines; user manual). Stable TET-ON cell lines were established prior to the second step designed to develop double-stable cell lines expressing the product of interest (see Clontech manual). Over 30 clones were generated. The clones used in this work were clone 10-19C1 for p53 [67 ± 303] and clone 4C9 for p53 [98 ± 303] . The p53 binds the nuclear matrix in normal cells M Jiang et al double-stable cell lines were selected and maintained in the presence of 1000 mg/ml G418 (Calbiochem) and 300 mg/ml Hygromycin (Life Technologies).
Immunofluorescence
The cells were grown on coverslips (13 mm diameter), ®xed for 10 min with 0.5 ml 4% paraformaldehyde (Sigma), washed with PBS and permeabilized with PBS+0.2% Triton X-100 for 10 min. The cells were washed four times with PBS for 5 min each time. The cells were then blocked with 5% normal rabbit serum (Sigma) in PBS for 30 min. For p53 [67 ± 303] and p53 [98 ± 303] staining, PAb246 mouse monoclonal antibody and FITC-conjugated rabbit antimouse IgG (Dako) were used as described in Rubbi and Milner (2000) .
Immunoprecipitation and immunoblotting
Cells (1610 6 ) were harvested and lysed with lysis buer A (150 mM NaCl, 0.5% NP-40, 50 mM Tris pH 8.0) on ice for 30 min. The cells were then centrifuged at 10 000 g, 48C for 10 min, and the supernatants were recovered for immunoprecipitation (IP). The IPs were performed with mouse conformational speci®c p53 monoclonal antibodies Pabs 240, 246 and 1620, as described in Milner et al. (1993) . For p53 [67 ± 303] protein, the IP samples were detected by immunoblotting with PAb240. However this procedure was not applicable for p53 [98 ± 303] which migrates on SDS ± PAGE with antibody light chain. Therefore cells were metabolically labelled with 35 [S]-methionine followed by immunoprecipitation and autoradiography to determine the conformation of p53 [98 ± 303] . For immunoblotting, the nitrocellulose blots were blocked with 1% blocking reagent (Boehringer Mannheim) in TBS (20 mM Tris pH 7.5, 500 mM NaCl) at room temperature for 1 h before they were probed with PAb240 in TBS with 0.5% blocking agent for 1 h. The blots were subsequently washed in TBST (TBS+0.1% Tween-20) and probed with secondary HRP-conjugated antibody for 1 h. After ®nal washing with TBST, the immunodetection was carried out using enzyme chemiluminescence detection following the manufacturer's recommendations (Boehringer Mannheim). 15% SDS ± PAGE gels were used throughout. Quantitation by gel scanning (Figure 1e ) employed exposures within the linear range.
Cell fractionation
Cell fractionation protocols were essentially as described by Spector et al. (1998) . To separate the cytoplasm and nuclei, cells were harvested and washed in PBS, and resuspended in ice-cold Buer A (20 mM HEPES pH 7.6, 100 mM KCl, 5% Sucrose, 0.25 mM EGTA, 0.5 mM DTT). An equal volume of ice-cold Buer B (Buer A+0.8% NP40) was added and the mixture was incubated on ice for 10 min. The cell mixture was then centrifuged at 5000 g, 48C, for 10 min and the supernatant was collected as soluble cytoplasm fraction. The pellet was resuspended in 100 ml Buer A and laid onto a 1.2 ml cushion consisting of 0.8 M sucrose in Buer A. After centrifugation at 5000 g, 48C, for 10 min, the pellet (nuclei) was collected and washed with Buer A. The integrity of the nuclei was checked by Trypan blue staining. At this stage half the nuclear sample was retained (nuclei) and half was subjected to further fractionation. At each of the following fractionation steps an aliquot was reserved for analysis by immunoblotting, and gel loading was adjusted to give equivalent cell numbers in each lane. The isolated nuclei were washed with PBS and ®rst extracted with extraction buer (EB) (10 mM PIPES pH 6.8, 250 mM ammonium sulphate, 300 mM sucrose, 3 mM MgCl 2 , 1 mM EGTA, 1 mM PMSF, RNasin) at 48C, for 5 min and centrifuged at 5000 g for 5 min. For comparison with previous studies (Staufenbiel and Deppert, 1983) it should be noted that chromatin extraction in the presence of 250 mM ammonium sulphate, as used in this study, is similar to that obtained in the presence of 2 M NaCl, as used by Staufenbiel and Deppert (1983) . The pellets were then digested with RNasefree DNase I (5 units/incubation) in digestion buer (10 mM PIPES pH 6.8, 300 mM sucrose, 50 mM NaCl, 3 mM MgCl 2 , 1 mM EGTA, 0.5% Triton X-100, 1 mM PMSF, RNasin: total 100 ml per incubation) at 328C for 1 h, centrifuged at 5000 g for 5 min, and washed with EB (without RNasin). The pellets were then digested with RNase A (10 mg/ml ®nal concentration) in digestion buer (as above but without RNasin) for a further 30 min and centrifuged at 5000 g for 5 min to separate the nuclear matrix and intermediate ®lament fraction (pellets) and supernatant (`RNase A' fraction). The nuclear matrix fraction was negative for histone 2A (not shown), but contained lamin B1 as expected (Figure 1 ).
Cell cycle analysis
Cells were harvested and washed with ice-cold PBS and ®xed with 90% ethanol at 7208C overnight. The ®xed cells were centrifuged and gently washed with PBS. The cells were stained with PAb240 followed by FITC-conjugated secondary antibody. The cells were then resuspended in PBS with 0.1 mg/ml PI+200 U/ml RNase A before carrying out FACS analysis. For transiently transfected MEF p53 7/7 cells the DNA content was quantitated using a Zeiss LSM410 laser scanning confocal microscope and the p53-expressing cells were identi®ed by immunostaining with FITC-conjugated Pab240. Total PI¯uorescence intensity for each nucleus was calculated and plotted as histograms and the numbers of p53-positive in each DNA population (2N and 4N) were counted. The p53-negative cells within the same ®eld were used as cell cycle controls. Between 100 to 300 cells were quantitated for each experimental point. The validity of this approach was con®rmed by FACS analysis of non-transfected MEF p53 7/7 cells cultured under identical conditions.
